4.6 Schleicher, GammaMed and MammoSite - Varian
4.6 Schleicher, GammaMed and MammoSite - Varian
4.6 Schleicher, GammaMed and MammoSite - Varian
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Gammamed<br />
<strong>and</strong> <strong>MammoSite</strong><br />
for breast IORT<br />
Breast Cancer Center Düren<br />
U M <strong>Schleicher</strong>, E M Bosch, W Hürter<br />
Radiotherapy<br />
L Paas, M Türker<br />
Gynaecology
Methods of partial breast irradiation<br />
Percutaneous<br />
– conformal 3D planned<br />
Interstitial<br />
– Iridium wires<br />
– Balloon catheter<br />
Intraoperative<br />
– Electrons<br />
– X-rays
ASTRO criteria for APBI as sole<br />
Suitable<br />
IJROPB 2009<br />
74:987-1001<br />
treatment
ASTRO criteria for APBI as sole<br />
cautionary:<br />
IJROPB 2009<br />
74:987-1001<br />
treatment
ASTRO criteria for APBI as sole<br />
Unsuitable:<br />
IJROPB 2009<br />
74:987-1001<br />
treatment
PBI- the German situation<br />
S3 Guidelines for breast cancer treatment<br />
– partial breast irradiation as a tumor bed boost before<br />
or after whole breast irradiation<br />
– may be performed with<br />
Electrons<br />
Interstitial: multicathter- or balloncatheter techniques<br />
3D-conformal percutaneous<br />
Protons only experimental<br />
Intraoperativ<br />
– Electrons or X-rays<br />
– technique does not influence results of therapy
PBI- the German situation<br />
Federal Ministry for Nuclear Safety on breast<br />
IORT with X-ray (June 2011):<br />
– only as boost with obligatory percutaneous WBI<br />
– Physician <strong>and</strong> Physicist must have the<br />
qualification in radiation protection for<br />
radiotherapy<br />
– Individual treatment plan obligatory
TARGIT Results:<br />
Non-inferiority to WBI<br />
Vaidya et al.: www.thelancet.com Published online June 5, 2010<br />
DOI:10.1016/S0140-6736(10)60837-9
Vaidya et al.: Lancet 2010<br />
TARGIT: Method<br />
•50 kV-X-ray, different applicator sizes<br />
•20 Gy on applicator surface = 5-7 Gy in 1 cm depth<br />
© Zeiss
Dose distributions<br />
Recommended for 3Dconformal PBI<br />
•CTV =lumpectomy cavity +1.5 cm<br />
5 mm from the skin surface<br />
5 mm from the lung–chest wall interface<br />
• PTV = CTV<br />
+0.5 cm for breathing motion<br />
+0.5 cm for expected variation in patient setup<br />
Offersen, Overgaard, Kromann, Overgaard,<br />
RadiotherOncol 2009; 90:1-13<br />
© ESO
Treatment Modality for IORT<br />
spherical isodose<br />
Sufficient dose<br />
distribution<br />
Easy to perform<br />
No time-consuming<br />
planning possible<br />
(anaesthesia!)<br />
Obeyence of legal<br />
restrictions
Material<br />
© <strong>Varian</strong> Medical Systems<br />
© Medicor
Dose distribution<br />
Dose<br />
(Gy)<br />
12<br />
10<br />
8<br />
6<br />
4<br />
2<br />
0<br />
4<br />
Dose in 1cm depth<br />
4,5<br />
5<br />
5,5<br />
balloon diameter (cm)
NSBAP B-39 RTOG 04-13<br />
Placement into closed cavity (post surgery)<br />
3D treatment planning<br />
PTV = breast tissue 1cm around balloon<br />
3,4 Gy bid for 5 treatment days<br />
6 h interval<br />
34 Gy total dose<br />
Deflation of balloon <strong>and</strong> removal (-> seroma<br />
in cavity?)
Treatment Modality for IORT<br />
spherical isodose<br />
Sufficient dose<br />
distribution<br />
Easy to perform<br />
No time-consuming<br />
planning possible<br />
(anaesthesia!)<br />
Obeyence of legal<br />
restrictions<br />
one stop point<br />
Gamma Energy :<br />
– γ 316 keV (86%)<br />
Single catheter<br />
St<strong>and</strong>ard plans for<br />
different volumes<br />
Informed consent<br />
(IORT <strong>and</strong> EBRT)<br />
Brachytherapy qualification of<br />
doc <strong>and</strong> physicist
Informed Consent<br />
for percutaneous <strong>and</strong> IORT
Patient Check-List<br />
Radiotherapy parts:<br />
filled in by<br />
radiotherapist<br />
Senology parts:<br />
filled in by<br />
gynaegologist
Performance<br />
Indication für BCS <strong>and</strong> boost RT<br />
Tumor > 1.5 cm from skin <strong>and</strong> chest wall<br />
Informed consent of patient<br />
Tumor excision, ballon placement<br />
Transport to brachytherapy unit<br />
IORT (20 Gy surface = 8.8-10 Gy in 1 cm)<br />
Transport to operation theatre<br />
Finishing of oncoplastic surgery
Dose measurement<br />
5-fold semiconductor probe<br />
Dose limit: 8 Gy
100<br />
80<br />
60<br />
40<br />
20<br />
0<br />
10<br />
8<br />
6<br />
4<br />
2<br />
0<br />
Patients<br />
aged 36-82 ys., 16 G2 + 4 G3<br />
Tumor stage: all patients=220/128)<br />
BZ DN KH DN<br />
Tis T1 T2 T3 T4<br />
ASTRO criteria for PBI only<br />
suitable cautionary unsuitable<br />
14<br />
12<br />
10<br />
8<br />
7<br />
6<br />
5<br />
4<br />
3<br />
2<br />
1<br />
0<br />
8<br />
6<br />
4<br />
2<br />
0<br />
Tumor Stage IORT<br />
T1a T1b T1c T2<br />
Mammosite volume<br />
35 ml 40 ml 50 ml
Side effects<br />
After 5 days After 6 weeks<br />
Erythema 3/20 3/20<br />
Epitheliolysis none none<br />
Pigmentation none 1/20<br />
Edema 4/20 1/20<br />
Seroma 3/20 1/20<br />
Induration 5/20 8/20<br />
No toxicity grade 3
Cosmetic results: patients‘ view<br />
patients<br />
18<br />
16<br />
14<br />
12<br />
10<br />
8<br />
6<br />
4<br />
2<br />
0<br />
grade 0 grade 1 grade 2 grade 3<br />
5 days 6 weeks 3 months
Advantages <strong>and</strong> Disadvantages of<br />
mammosite vs. intrabeam<br />
dose distribution<br />
– 8.8 to 10 Gy vs. 5-7 Gy in 1 cm<br />
– applicator-skin distance 1.5 vs. 1 cm<br />
online dose measurement<br />
equal time for treatment<br />
– including transport to brachytherapy unit<br />
brachytherapy unit existing -> no investment in<br />
machines, payment for catheters per patient<br />
treated -> IORT possible in smaller breast units